Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 64 HER2-positive Breast Cancer 11 Carcinoma, Non-Small-Cell Lung 6 HER2 Positive Metastatic Breast Cancer 4 Breast Diseases 4 Brain Neoplasms 4 HER2 Positive Breast Cancer 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

pembrolizumab 155 Gemcitabine 139 Capecitabine 121 Paclitaxel 118 Fluorouracil 116 Oxaliplatin 110 Bevacizumab 104 Nivolumab 97 Leucovorin 97 Docetaxel 92 Cisplatin 89 Irinotecan 87 Carboplatin 84 Radiosurgery 83 Cyclophosphamide 70 Cetuximab 70 Magnetic Resonance Spectroscopy 68 Trastuzumab 56 Specimen Handling 56 Biopsy 56 Radiotherapy 55 Ipilimumab 52 Everolimus 48 Pemetrexed 46 Drug Therapy 45 Albumin-Bound Paclitaxel 44 130-nm albumin-bound paclitaxel 43 Doxorubicin 41 Fulvestrant 38 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm Metastasis × pyrotinib × Clear all

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡